About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Resmiterom Efficacy & Safety in Patients With MASH | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGPhase 4NCT07249788

Resmiterom Efficacy & Safety in Patients With MASH

Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.

Lead sponsor: Nabiqasim Industries (Pvt) Ltd•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Hussain B Abidi, MBBS, MBA, CRCP

CONTACT

+923322583236 MDR.hussainabidi@gmail.com

Sponsors

Lead Sponsor

Nabiqasim Industries (Pvt) Ltd

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•• At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension)
•* Clinical diagnosis of MASH using:
•* LSM ≥ 8.5kpa And/or
•* FAST score ≥0.67 And/or
•* FibroScan CAP ≥ 275 dB/m And/or
•* FIB-4 \> 1.3

Exclusion Criteria

•• History of drug addiction and alcoholism
•* Cirrhosis or decompensated liver disease
•* Chronic viral hepatitis HBV, HCV)
•* MACE including MI, Stroke, PE etc.
•* Pregnant/lactating women
•* Concurrent use of other investigational drugs
•* History of other liver diseases (viral, autoimmune, drug-induced, alcohol)
•* Previous use of resmetirom in last 6 months
•* Significant renal impairment (eGFR \<30)

Related studies

Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients

NCT06661655 · Metabolic Syndrome X, Fatty Liver, and more

Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07013916 · MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH With Fibrosis, and more

Active Not RecruitingPhase 2

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

NCT07335601 · MASH - Metabolic Dysfunction-Associated Steatohepatitis

Not Yet RecruitingPhase 2

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

NCT07303803 · MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 3, 2025Terms

Trial snapshot

StatusRECRUITING

PhasePHASE4

Enrollment165

Start dateOct 2025

Last updatedDec 3, 2025

Condition

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Locations shown

Liver transplant center, Holy family hospital

Rawalpindi, Punjab Province

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 3, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions